BR112013010288A2 - método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado - Google Patents

método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado

Info

Publication number
BR112013010288A2
BR112013010288A2 BR112013010288A BR112013010288A BR112013010288A2 BR 112013010288 A2 BR112013010288 A2 BR 112013010288A2 BR 112013010288 A BR112013010288 A BR 112013010288A BR 112013010288 A BR112013010288 A BR 112013010288A BR 112013010288 A2 BR112013010288 A2 BR 112013010288A2
Authority
BR
Brazil
Prior art keywords
animal
protect
biotype
vaccine
microorganism
Prior art date
Application number
BR112013010288A
Other languages
English (en)
Inventor
Delbert Linn Harris
John Dustin Loy
Jonathan Smith
Kurt Iver Kamrud
Lyric Colleen Bartholomay
Matt Erdman
Original Assignee
Harrisvaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harrisvaccines Inc filed Critical Harrisvaccines Inc
Publication of BR112013010288A2 publication Critical patent/BR112013010288A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/18011—Nimaviridae
    • C12N2710/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/18011—Nimaviridae
    • C12N2710/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
BR112013010288A 2010-10-27 2011-10-19 método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado BR112013010288A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40729710P 2010-10-27 2010-10-27
US41843310P 2010-12-01 2010-12-01
US201161449940P 2011-03-07 2011-03-07
US201161484255P 2011-05-10 2011-05-10
US201161508172P 2011-07-15 2011-07-15
US201161525332P 2011-08-19 2011-08-19
PCT/US2011/056945 WO2012058072A1 (en) 2010-10-27 2011-10-19 Method of rapidly producing vaccines for animals

Publications (1)

Publication Number Publication Date
BR112013010288A2 true BR112013010288A2 (pt) 2016-09-20

Family

ID=44863284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010288A BR112013010288A2 (pt) 2010-10-27 2011-10-19 método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado

Country Status (6)

Country Link
US (3) US8828961B2 (pt)
EP (2) EP2632486A1 (pt)
BR (1) BR112013010288A2 (pt)
TW (1) TWI643950B (pt)
WO (2) WO2012058073A2 (pt)
ZA (1) ZA201303430B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
MX2012010479A (es) 2010-03-08 2012-10-09 Monsanto Technology Llc Moleculas polinucleotidicas para regulacion genetica en plantas.
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
WO2012058073A2 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Methods and compositions to protect aquatic invertebrates from disease
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
UA116090C2 (uk) 2011-09-13 2018-02-12 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
PL2755467T3 (pl) 2011-09-13 2018-01-31 Monsanto Technology Llc Sposoby i kompozycje do kontroli chwastów
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
WO2013066665A1 (en) * 2011-10-19 2013-05-10 Harrisvaccines, Inc Method of rapidly producing improved vaccines for animals
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
AU2013371825B2 (en) 2013-01-01 2019-10-24 A.B. Seeds Ltd. Methods of introducing dsRNA to plant seeds for modulating gene expression
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UA123082C2 (uk) 2013-03-13 2021-02-17 Монсанто Текнолоджи Ллс Спосіб та гербіцидна композиція для боротьби з видами рослин роду sorghum
AR095233A1 (es) 2013-03-13 2015-09-30 Monsanto Technology Llc Métodos y composiciones para el control de malezas
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
CA2918387C (en) 2013-07-19 2021-11-02 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
NZ719544A (en) 2013-11-04 2022-09-30 Beeologics Inc Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
EP3420809A1 (en) 2014-04-01 2019-01-02 Monsanto Technology LLC Compositions and methods for controlling insect pests
CN106795515B (zh) 2014-06-23 2021-06-08 孟山都技术公司 用于经由rna干扰调控基因表达的组合物和方法
EP3161138A4 (en) 2014-06-25 2017-12-06 Monsanto Technology LLC Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
WO2016018887A1 (en) 2014-07-29 2016-02-04 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
UY36703A (es) 2015-06-02 2016-12-30 Monsanto Technology Llc Composiciones y métodos para la administración de un polinucleótido en una planta
AU2016270913A1 (en) 2015-06-03 2018-01-04 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
JP2019500025A (ja) * 2015-11-18 2019-01-10 オービス ヘルス ソリューションズ エルエルシー Ｔ７アルファウイルスベクター系
CN109689106B (zh) * 2016-04-26 2023-01-24 微而广治疗有限公司 治疗虾类病毒感染的组合物和方法
MX2019011490A (es) * 2017-03-31 2020-01-23 Pebble Labs Usa Inc Sistema novedoso para el biocontrol de patógenos en sistemas de acuicultura y otros sistemas animales.
US11446339B2 (en) 2017-03-31 2022-09-20 Pebble Labs Inc. System for the biocontrol of white spot syndrome virus (WSSV) in aquaculture
WO2019032629A1 (en) 2017-08-07 2019-02-14 Pebble Labs Inc. SYSTEMS AND METHODS FOR FIGHTING ACUTE HEEPATOPANCREATIC NECROSIS DISEASE
CN109142560B (zh) * 2018-07-06 2021-03-02 浙江工商大学 PEG-ACS/luxR-siRNA纳米复合物及其应用和降低凡纳滨对虾中生物胺的方法
CN109468415A (zh) * 2018-12-29 2019-03-15 四川出入境检验检疫局检验检疫技术中心 一种传染性肌肉坏死病毒的检测方法
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
WO2021058145A1 (en) * 2019-09-24 2021-04-01 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Phage t7 promoters for boosting in vitro transcription
CN110735005B (zh) * 2019-11-26 2023-01-10 广西大学 Siv和prrsv多重rt-pcr快速检测试剂盒及引物
EP4149484A1 (en) * 2020-05-15 2023-03-22 ModernaTX, Inc. Rna formulations for high volume distribution
WO2023084510A1 (en) 2021-11-09 2023-05-19 Viaqua Therapeutics Ltd. Compositions for aquaculturing

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692412A (en) 1972-10-06 1987-09-08 Livingston Virginia W Method of preparing an autogenous vaccine
US4285931A (en) 1978-01-30 1981-08-25 Merck & Co., Inc. E. coli enterotoxin vaccine for veterinary and human use
US4220584A (en) 1978-01-30 1980-09-02 Merck & Co., Inc. E. coli enterotoxin vaccine for veterinary and human use
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6086880A (en) 1985-12-26 2000-07-11 The University Of Saskatchewan Rotavirus peptide compositions and methods of use
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
GB8612087D0 (en) 1986-05-19 1986-06-25 Ici Plc Hybridisation probes
US5017478A (en) 1987-07-16 1991-05-21 Berlex Laboratories, Inc. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5824535A (en) 1996-01-17 1998-10-20 Kou; Guang-Hsiung Identification, purification and detection of WSBV (Baculovirus associated with white spot syndrome)
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
SK287538B6 (sk) 1998-03-20 2011-01-04 Commonwealth Scientific And Industrial Research Organisation Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
CN1170934C (zh) 1999-08-03 2004-10-13 阿克佐诺贝尔公司 源自白斑综合征病毒的蛋白质及其应用
JP2003508056A (ja) 1999-08-31 2003-03-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル アルファウイルス感染の抗体依存性増強（ａｄｅ）
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001269936A1 (en) 2000-06-20 2002-01-02 Phycotransgenics, Llc Transgenic algae for delivering antigens to an animal
CN1193094C (zh) 2000-09-15 2005-03-16 阿克佐诺贝尔公司 虾白斑综合征病毒抗原蛋白及其用途
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
WO2003012052A2 (en) 2001-07-30 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Specific inhibition of gene expression by small double stranded rnas
EP1429623B1 (en) 2001-08-27 2009-10-21 Advanced Bionutrition Corporation Delivery of disease control in aquaculture and agriculture using nutritional feeds containing bioactive proteins produced by viruses
JP4790984B2 (ja) 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
US20030203868A1 (en) 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
ES2346645T3 (es) 2002-03-14 2010-10-19 Commonwealth Scientific And Industrial Research Organisation Procedimientos y medios de supervision y modulacion del silenciamiento genico.
CN1646687A (zh) 2002-03-14 2005-07-27 联邦科学和工业研究组织 修饰的基因沉默rna及其用途
JP4731907B2 (ja) 2002-09-16 2011-07-27 アドバンスド バイオニュートリション コーポレーション 受動免疫のための蛋白質およびペプチド発現
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
CN1791678A (zh) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
GB0306715D0 (en) 2003-03-24 2003-04-30 Novartis Ag Organic compounds
JP5183064B2 (ja) 2003-07-02 2013-04-17 エムユーエスシー ファウンデイション フォー リサーチ デべロップメント 甲殻類動物、及び他の無脊椎動物における、ｄｓＲＮＡで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体
US20070059808A1 (en) 2003-09-09 2007-03-15 Aqua Bounty Technologies, Inc. Compositions and methods for inhibiting white spot syndrome virus (wssv) infection
WO2005047300A2 (en) 2003-11-10 2005-05-26 University Of Utah Research Foundation Improved methods and compositions for rna interference
AU2005213981A1 (en) 2004-02-06 2005-09-01 Advanced Bionutrition Corporation RNA-mediated interference to control disease in terrestrial and aquaculture animals
WO2005084312A2 (en) 2004-02-27 2005-09-15 San Diego State University Foundation Disease control in shrimp
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
CN106075422B (zh) 2005-11-29 2021-05-28 衣阿华州立大学研究基金公司 猪繁殖与呼吸综合征病毒(prrsv)的保护性抗原决定子的鉴定及其用途
WO2007084499A2 (en) 2006-01-13 2007-07-26 San Diego State University Disease control in shrimp
AU2007224430A1 (en) 2006-03-15 2007-09-20 Intervet International B.V. Recombinant Newcastle disease virus expressing H5 hemagglutinin of avian influenza virus
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US7323547B2 (en) 2006-05-22 2008-01-29 National Taiwan University Highly expressed peptide of white spot syndrome virus in hosts and application thereof
WO2008027235A1 (en) 2006-08-25 2008-03-06 University Of New Mexico Methods and compositions for control of disease in aquaculture
EP2066346B1 (en) 2006-09-12 2019-07-03 AlphaVax, Inc. Alphavirus replicon particles encoding il-12 as immunological adjuvants
WO2012058073A2 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Methods and compositions to protect aquatic invertebrates from disease

Also Published As

Publication number Publication date
US20120107355A1 (en) 2012-05-03
US8828961B2 (en) 2014-09-09
US20120108649A1 (en) 2012-05-03
EP2632486A1 (en) 2013-09-04
US9650634B2 (en) 2017-05-16
EP2633049A2 (en) 2013-09-04
WO2012058073A2 (en) 2012-05-03
WO2012058073A3 (en) 2012-08-30
TWI643950B (zh) 2018-12-11
ZA201303430B (en) 2018-12-19
TW201303015A (zh) 2013-01-16
EP2633049B1 (en) 2018-10-10
WO2012058072A1 (en) 2012-05-03
US20140371295A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
BR112013010288A2 (pt) método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
SMT201400079B (it) Produzione di poliovirus ad alti titoli per la produzione di vaccino
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
DK3170508T3 (da) Vaccineformuleringer
CO6862126A2 (es) Sistema de guía quirúrgica para implantología dental y método para hacer un sistema de guía quirúrgica para implantología dental
BRPI1012635A2 (pt) "métodos e composições para imunização contra o vírus"
ZA201309386B (en) Vaccine composition comprising an inactivated chikungunya virus strain
BR112013029968A2 (pt) oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
BR112013001514A2 (pt) vacina para influenza
BR112013031760A2 (pt) vacina contra coronavírus canino
BR112014005756A2 (pt) vacina
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
BR112014006668A2 (pt) sistema liberador de ácaro predador fitoseídeo, utilização de um ácaro anfitrião, método produzir um sistema liberador de ácaros predadores fitoseídeos, e utilização do sistema liberador de ácaro predador fitoseídeo
IN2015KN00516A (pt)
BR112014009887A2 (pt) vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue
BR112013029514A2 (pt) composição imunogênica, vacina, e, método de tratar ou impedir uma doença
DK2609931T3 (da) Immunogen sammensætning
PT2575872T (pt) Concentração de antigénios da vacina da gripe sem liofilização
BR112012022059A2 (pt) vacina de mucosa produtora de uma iga de mucosa antígeno-específica e igg do sangue e método para produzir uma vacina de mucosa produtora de uma iga de mucosa antígeno-específica e uma igg do sangue
IL222360A0 (en) Method of vaccination
EP2694102A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
EP3053594A4 (en) Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
DK2938356T3 (da) Immunogen sammensætning som omfatter mycoplasma-antigener
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2501 DE 11/12/2018 POR TER SIDO INDEVIDA.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]